20 July 2020
Metastatic prostate cancer hijacks DNA program for embryonic development
Metastatic prostate cancer cells that spread throughout the patient’s body reactivate a DNA program responsible for fetal prostatic development, new research shows. Cancer researchers led by Oncode Investigator Wilbert Zwart (NKI) and Matthew Freedman of the Harvard Dana-Farber Cancer Institute in Boston, demonstrated this process in tissue samples taken from hundreds of surgically removed prostate tumors.
9 July 2020
Oncode funds project on clinical implementation of the MeD-seq assay
We are pleased to announce that the 11th grant within the cPoC programme has been awarded to Oncode Investigator Joost Gribnau (Erasmus MC). Together with colleagues, he will work on the clinical implementation of their recently developed MeD-seq assay. The goal of the project is to deliver proof of concept of the clinical applicability of their MeD-seq assay, which is able to detect tumor-specific epigenetic patterns in the circulating cell-free DNA in the blood of patients. The researchers will evaluate whether this assay can predict early recurrence in colorectal cancer patients with surgically removable liver metastases.
30 June 2020
New colleagues at Oncode Institute
We are pleased to welcome Saharla Ahmed and Colette ten Hove to Oncode Institute. Saharla started as a Business Developer in the Valorization Team and Colette joined as a new Programme Manager in the General Support Team. We asked them to describe their role within Oncode briefly.
30 June 2020
Oncode Institute appoints Alain Kummer as its new Managing Director
Oncode Institute today announced that its Supervisory Board has appointed Alain Kummer as Managing Director per September 1st, 2020. On the same day, Ton Rijnders, Oncode’s General Director, will step down from his position. As of September 1st, the new Oncode Managing Board will consist of Geert Kops (Scientific Director and Head of the institute), Chris De Jonghe (Valorization Director) and Alain Kummer (Managing Director).
22 June 2020
New research: multiple low dose therapy
Combining low doses of several cancer drugs at the same time might overcome the important problem of resistance, researchers from the Netherlands Cancer Institute conclude. The lab of Oncode Investigator Rene Bernards shows promising results for this multiple low dose approach. Their paper is published in the scientific journal Nature Communications on June 22nd.
19 June 2020
Two Oncode Investigators awarded the highest distinction in Dutch Science
Two Oncode Investigators will receive the highest awards in science. Professor Sjaak Neefjes (LUMC) will be awarded the Spinoza Prize and professor Ton Schumacher (NKI) will receive the Stevin Prize. Each laureate will receive 2.5 million euros, which they can spend on scientific research and activities related to knowledge utilisation.
18 June 2020
Oncode Oncology Bridge Fund appoints Investment Advisory Committee
The Oncode Oncology Bridge Fund provides early stage financing to support the creation and growth of new enterprises based on highly innovative science performed by researchers at the Oncode Institute. We are proud to announce that the Bridge Fund has appointed its Investment Advisory Committee (IAC). The role of the IAC is to review and make recommendations on investment proposals presented by the Fund Managers.
27 May 2020
New facilities available for Oncode researchers
We are pleased to announce that three facilities are now open to the whole Oncode research community. The goal of Oncode Institute is to translate the results of ground-breaking fundamental research into the clinic faster, in order to improve the chances of cancer patients. Instead of competition between scientists, Oncode encourages collaboration. Investing in facilities which can be used by all Oncode researchers, is one of the ways in which Oncode wants to contribute to breakthroughs in cancer research.
22 May 2020
In Memoriam: Professor Huib Ovaa
On the 19th of May 2020, our dear colleague Professor Dr. Huib Ovaa passed away from prostate cancer. In the past year, Huib has undergone a variety of treatments, and has done so with his usual optimism. He continued to work as much as possible and tried to keep the burden of his fight against cancer away from the people around him. Huib was 46 years of age.
15 May 2020
Oncode Institute is in Top 50 NPO/NGOs ranked by Nature Index
We are honoured to announce that Nature Index included Oncode Institute in its Top 50 NPO/NGO institutions in cancer research worldwide. Every year, Nature Index publishes its Cancer supplement, featuring a list of the most prominent institutes and academic, healthcare, NPO/NGO, government and corporate institutions working in cancer research.
Scroll for more